Do you routinely continue patients on anti-PD(L)-1 beyond 2 years of treatment while on IO/TKI for metastatic ccRCC?

I routinely continue anti-PD(L)-1 beyond 2 years while on IO/TKI for patients with clear cell RCC.

Of course, this is assuming the patient is tolerating therapy well, continues to be with stable disease/response, and prefers continuation of therapy.

I do have a discussion with them at the 2-year mar...

For the first-line treatment of patients with advanced RCC for all (favorable, intermediate, or poor) risk groups, axitinib in combination with pembrolizumab has shown a significantly higher overall response rate (ORR) and longer PFS based on the randomized phase III KEYNOTE-426 trial. (Rini et al.,...